1255871-41-0

Upstream product

• 106-93-4 ethylene dibromide 
• 118650-08-1 (5-bromo-pyridin-3-yl)-acetic acid methyl ester 
• 186581-53-3 diazomethane 
• 1256038-40-0 1-(5-bromo-3-pyridinyl)cyclopropanecarboxylic acid 
• 39891-12-8 5-bromo-3-pyridineacetic acid 

Downstream Products

• 1255871-43-2 potassium 1-(5-bromopyridin-3-yl)cyclopropanecarboxylate 
• 1255871-47-6 4-(5-(1-aminocyclopropyl)pyridin-3-yl)-2-chlorobenzonitrile 
• 1255871-45-4 1-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)cyclopropanecarboxylic acid 
• 1255870-31-5 N-(1-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)cyclopropyl)ethanesulfonamide 
• 1369503-74-1 [1-(5-bromo-3-pyridinyl)cyclopropyl]methanol 
• 1256038-40-0 1-(5-bromo-3-pyridinyl)cyclopropanecarboxylic acid 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS

The present invention provides a compound of Formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.